Emergent BioSolutions Inc. (NYSE: EBS) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $288M. The Maz Rating grades it against the other companies in its sector.
Emergent BioSolutions Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $5.61, Emergent BioSolutions Inc. trades at 0.4x sales and 0.9x book value. Over the last twelve months it generated about $641M of revenue and a net loss of $256M. It runs a gross margin of 41.6%, an operating margin of -26.0% and a net margin of -40.2%. It shows return on equity of -61.3%, return on invested capital of -19.3% and a free cash flow yield of 65.1%. On the balance sheet: a debt-to-equity ratio of 1.62 and a current ratio of 4.58. Over the past 52 weeks the share price ranged from $4.36 to $14.06, with a beta of 2.37.
Emergent BioSolutions Inc. does not currently pay a dividend.
15 Wall Street analyst ratings cover the stock: 11 Buy, 3 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.